Biotech Startups

Sensible Biotechnologies develops a cell-based mRNA design and manufacturing platform that produces pure, low immunogenicity mRNA therapeutics for drug development. The platform addresses limitations of synthetic mRNA by enabling design-based biology approaches.

5 investors

Sera Prognostics develops women's health diagnostics focused on pregnancy, including the PreTRM blood test that predicts an individual's risk of spontaneous preterm birth in singleton pregnancies and the LikeMine platform that compares pregnancy outcomes using U.S. pregnancy data. Its products serve pregnant women and their physicians in the maternal-fetal and prenatal diagnostics market.

5 investors

SFA Therapeutics develops oral therapeutic candidates based on deuterated short-chain fatty acids to treat autoimmune and oncologic diseases. The company's lead program, SFA-002, is in Phase 2 development for plaque psoriasis, with additional pipeline assets targeting pancreatic cancer, liver cancer, rheumatoid arthritis, and inflammatory bowel disease.

5 investors

Shellworks develops VIVOMER, a compostable material made by collaborating with microorganisms that produce natural polymers, designed to perform like plastic but break down without leaving waste. The company works with manufacturers using existing infrastructure to replace conventional permanent plastics.

5 investors

ShennonBio develops immunotherapy technologies using microfluidic engineering, computational biology, and immunology to advance T cell engineering for cancer treatment. The company serves therapeutic development organizations working on cell and gene therapies.

5 investors

Shinobi develops next-generation cell therapies using iPSC (induced pluripotent stem cell) research, genetic engineering, and clinical infrastructure. The company operates across Japan and the U.S., combining biotechnology and genetic engineering capabilities in cell therapy development.

5 investors

Sibylla Biotech develops PPI-FIT, a drug discovery technology that uses quantum physics and mathematical modeling to characterize protein folding pathways at atomic resolution. The company focuses on protein misfolding diseases, particularly prion diseases.

5 investors

Sidewinder Therapeutics is a biotechnology company focused on oncology drug discovery and development, working on next-generation cancer treatments.

5 investors

A biopharmaceutical company that discovers, develops, and delivers medicines and vaccines, with research and development across respiratory, immunology and inflammation, oncology, HIV, and infectious diseases.

5 investors

Sinaptica develops a noninvasive, personalized closed-loop rTMS-EEG neuromodulation therapy for Alzheimer's disease that stimulates the precuneus and Default Mode Network to slow disease progression. The therapy targets cognition, function, and behavior and is calibrated per patient using MRI and TMS-evoked potential data.

5 investors

SonoThera is developing a nonviral, non-invasive gene delivery technology that uses ultrasound and microbubbles (ultrasound-mediated delivery) to deliver genetic payloads to targeted sites in a redosable way. The company works on genetic medicine, aiming to address limitations in delivery, safety, durability, and cost.

5 investors

SOSV is a deep tech venture capital firm that makes pre-seed investments (up to $550k) in about 60 startups per year and joins follow-on rounds, backing founders in biotech, therapeutics, climate, energy, and physical AI. It operates labs and offices in San Francisco, New York City, and Newark, with additional teams in India, China, and the EU.

5 investors

Stämm develops a high-throughput bioprocessor for biomanufacturing, offering hardware for biologics production in research-use settings. It serves research and biopharmaceutical teams working on biologics.

5 investors

Star Therapeutics develops treatments aimed at addressing real-world patient needs.

5 investors

Step Pharma develops dencatistat (STP938), a first-in-class, orally bioavailable CTPS1 inhibitor in clinical development as a targeted oncology therapy for blood cancers such as lymphoma and essential thrombocythaemia as well as solid tumours including ovarian cancer. The company focuses on CTPS1 inhibition for cancer treatment.

5 investors

Stylus Medicine develops in vivo genetic medicines using engineered recombinases, with initial focus on creating CAR-T therapies delivered via lipid nanoparticles for oncology, autoimmune, and genetic diseases.

5 investors

Synchron develops brain-computer interface technology delivered via catheter to restore or improve motor and cognitive function in people with impairment or decline. The company serves patients with motor impairment and cognitive decline using a minimally invasive approach inspired by cardiac interventional procedures.

5 investors

Synthace provides software and expert services that help life sciences teams design, automate, run, and analyze high dimensional, multifactorial biology experiments and produce contextualized, AI-ready datasets. It targets drug discovery and R&D scientists in pharma and biotech organizations.

5 investors

Tagworks Pharmaceuticals develops cancer therapies using its Click-to-Release platform, a chemical reaction that activates antibody-drug conjugates (ADCs), masked immunomodulators, and other prodrugs on-target while deactivating radioimmunotherapies off-target. Its lead program targets TAG72, a non-internalizing marker expressed in difficult-to-treat solid tumors, aiming to expand ADC target scope and therapeutic window.

5 investors

TargED Biopharmaceuticals is a Netherlands-based biotechnology company developing first-in-class biological drugs that use small antibodies (VHH) to deliver enzymes to sites of thrombosis for targeted thrombolysis. Its lead compound, TGD001, is a targeted thrombolytic in preclinical development for thrombotic disorders including immune thrombotic thrombocytopenic purpura (iTTP) and acute ischemic stroke.

5 investors

Tarsus Rx is a pharmaceutical company developing treatments for diseases with high unmet need, with a lead product XDEMVY (lotilaner ophthalmic solution) approved by the FDA for Demodex blepharitis. It maintains a pipeline of therapies targeting large disease categories with limited treatment options.

5 investors

Theolytics develops systemically deliverable immunotherapies based on oncolytic adenoviruses designed to target solid tumours and their supporting microenvironment. It uses its Adenovo platform to screen large libraries of adenovirus variants in human systems to identify therapeutic candidates, with THEO-260 as its lead programme.

5 investors

Therini Bio is a biotechnology company developing therapies that block vascular-mediated inflammation to halt chronic neurological disease. Its candidates target neuro-related conditions and are being advanced through clinical development.

5 investors

Tierra Biosciences develops high-performance protein design technology, serving biotechnology and pharmaceutical industries.

5 investors